Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, has announced its participation in three upcoming investor conferences in September 2025.

The company will attend Citi's 2025 Biopharma Back to School Summit on September 3, the 2025 Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Management will conduct one-on-one meetings at all three events.

Foghorn's Gene Traffic Control® platform focuses initially on oncology applications, aiming to develop treatments for a broad spectrum of diseases.

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi’s 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Citi’s 2025 Biopharma Back to School Summit

• Date: Wednesday, September 3, 2025
• Management will participate in one-on-one meetings

2025 Wells Fargo Healthcare Conference

• Date: Thursday, September 4, 2025
• Management will participate in one-on-one meetings

Morgan Stanley 23^rd Annual Global Healthcare Conference

• Date: Monday, September 8, 2025
• Management will participate in one-on-one meetings
  
  

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.

Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com

FAQ

When is Foghorn Therapeutics (FHTX) presenting at the Wells Fargo Healthcare Conference 2025?

Foghorn Therapeutics will participate in the Wells Fargo Healthcare Conference on Thursday, September 4, 2025, where management will conduct one-on-one meetings.

What conferences will Foghorn Therapeutics (FHTX) attend in September 2025?

Foghorn will attend three conferences: Citi's Biopharma Back to School Summit (Sept 3), Wells Fargo Healthcare Conference (Sept 4), and Morgan Stanley Global Healthcare Conference (Sept 8).

What is Foghorn Therapeutics' (FHTX) main technology platform?

Foghorn Therapeutics utilizes its Gene Traffic Control® platform, which focuses on correcting abnormal gene expression to treat serious diseases, with an initial focus in oncology.

How can investors meet with Foghorn Therapeutics (FHTX) management at these conferences?

Management will be available for one-on-one meetings at all three conferences. Investors should contact their conference representatives to schedule meetings.